Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2309-2315

  Nzila, Alexis ^a   Okombo, John ^b   Ohuma, Eric ^c   Al Thukair, Assad ^a  

^a KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chloroquine; Drug resistance; Lumefantrine tolerance; Malaria; Pfmdr1 genotype

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; MEFLOQUINE; PFCRT PROTEIN; PFMDR1 PROTEIN; PROTOZOAL PROTEIN; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

ALLELE; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; CODON; DRUG EFFICACY; DRUG TOLERANCE; GENE DOSAGE; GENE LOCUS; GENE MUTATION; HAPLOTYPE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MONOTHERAPY; NONHUMAN; PLASMODIUM CHABAUDI; POINT MUTATION; REVIEW; STRAIN DIFFERENCE; WILD TYPE;

ANTIMALARIALS; ASIA, SOUTHEASTERN; CHLOROQUINE; DRUG RESISTANCE; DRUG TOLERANCE; ETHANOLAMINES; FLUORENES; GENOTYPE; HUMANS; MALARIA; PARASITIC SENSITIVITY TESTS; PLASMODIUM;

EID: 84866601471     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks252     Document Type: Review

References (43)

1. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113: 1084-92.
2. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18: 458-64.
3. WHO. Guidelines for the Treatment of Malaria. 2006. http://whqlibdoc.who.int/publications/2006/9241546948_eng.pdf (25 May 2012, date last accessed).
4. Makanga M, Bassat Q, Falade CO et al. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg 2011; 85: 793-804.
5. Makanga M, Krudsood S. The clinical efficacy of artemether/ lumefantrine (Coartem). Malar J 2009; 8 Suppl 1: S5.
6. Ministry of Health, Kingdom of Saudi Arabia. The National Policy of Malaria Case Management in the Kingdom of Saudi Arabia. Riyadh: Abakar Printing Co., 2008.
7. Omari AA, Gamble C, Garner P. Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev 2006; issue 2: CD005965.
8. Mårtensson A, Strömberg J, Sisowath C et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005; 41: 1079-86.
9. Sisowath C, Strömberg J, Mårtensson A et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemetherlumefantrine (Coartem). J Infect Dis 2005; 191: 1014-7.
10. WHO. Practical Chemotherapy of Malaria. WHO Tech Rep Ser 805. Geneva: WHO, 1990.
11. Welcome to Coartem.com, the Novartis Malaria Initiative website. http://www.coartem.com/MI-brochure/page6.htm (25 May 2012, date last accessed).
12. Adjei GO, Goka BQ, Binka F et al. Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children. Expert Rev Anti Infect Ther 2009;7: 669-81
13. Sanchez CP, Dave A, Stein WD et al. Transporters as mediators of drug resistance in Plasmodium falciparum. Int J Parasitol 2010; 40: 1109-18.
14. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27: 594-601.
15. Picot S, Olliaro P, de Monbrison F et al. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 2009; 8: 89.
16. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop 2005; 94: 181-90.
17. Hastings IM, Ward SA. Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis 2005; 192: 1303-4; author reply 1304-5.
18. German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 2008; 47: 91-102.
19. Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci 2002; 357: 505-19.
20. Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemetherlumefantrine in Uganda. J Infect Dis 2011; 204: 1120-4.
21. Dokomajilar C, Nsobya SL, Greenhouse B et al. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother 2006; 50: 1893-5.
22. Humphreys GS, Merinopoulos I, Ahmed J et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 2007; 51: 991-7.
23. Sisowath C, Petersen I, Veiga MI et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 2009; 199: 750-7.
24. Somé AF, Séré YY, Dokomajilar C et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemetherlumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 2010; 54: 1949-54.
25. Zongo I, Dorsey G, Rouamba N et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007; 369: 491-8.
26. Gadalla NB, Adam I, Elzaki SE et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother 2011; 55: 5408-11.
27. Happi CT, Gbotosho GO, Folarin OA et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2009; 53: 888-95.
28. Sisowath C, Ferreira PE, Bustamante LY et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 2007; 12: 736-42.
29. Price RN, Uhlemann AC, van Vugt M et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42: 1570-7.
30. Price RN, Uhlemann AC, Brockman A et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364: 438-47.
31. Uhlemann AC, Ramharter M, Lell B et al. Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis 2005; 192: 1830-5.
32. Borges S, Cravo P, Creasey A et al. Genomewide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine, and artemisinin in Plasmodium chabaudi malaria parasites. Antimicrob Agents Chemother 2011; 55: 4858-65.
33. Duraisingh MT, Roper C, Walliker D et al. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol 2000; 36: 955-61.
34. Mwai L, Kiara SM, Abdirahman A et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 2009; 53: 5069-73.
35. Nkhoma S, Nair S, Mukaka M et al. Parasites bearing a single copy of the multi-drug resistance gene (pfmdr-1) with wild-type SNPs predominate amongst Plasmodium falciparum isolates from Malawi. Acta Trop 2009; 111: 78-81.
36. Nsobya SL, Kiggundu M, Nanyunja S et al. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 2010; 54: 1200-6.
37. Veiga MI, Ferreira PE, Jörnhagen L et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One 2011; 6: e20212.
38. Warhurst DC, Duraisingh MT. Rational use of drugs against Plasmodium falciparum. Trans R Soc Trop Med Hyg 2001; 95: 345-6.
39. Laufer MK, Takala-Harrison S, Dzinjalamala FK et al. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis 2010; 202: 801-8.
40. Laufer MK, Thesing PC, Eddington ND et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006; 355: 1959-66.
41. Chloroquine Alone or in Combination for Malaria in Children in Malawi. www.clinicaltrials.gov/ct2/show/NCT00379821 (25 May 2012, date last accessed).
42. Bell DJ, Wootton D, Mukaka M et al. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J 2009; 8: 204
43. Wong RP, Salman S, Ilett KF et al. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother 2011; 55: 1194-8.